Accession Number:



Validation of Biomarkers for Prostate Cancer Prognosis

Descriptive Note:

Final rept. 30 Sep 2011-29 Sep 2014

Corporate Author:


Personal Author(s):

Report Date:


Pagination or Media Count:



Our objective is to create a multi-institutional tissue microarray resource from radical prostatectomy samples with detailed clinical information and follow-up and rigorous casecohort design for use as a platform for validating tissue biomarkers of prognosis. In addition, we have proposed testing a series of biomarkers of prognosis and a set of biomarkers that correlate with Gleason Score. We have made significant progress over the past year. Having completed construction of the tissue microarrays and finalized standard procedures for tissue microarray storage, sectioning and shipping, we have now stained scanned, gridded and read TMAs for several biomarkers. We have now changed to the Leica scanner and PathXL image analysis software suite for some of the biomarkers and have also used the Aperio system for others. Pathologists have read compete sets of TMAs for H E, High Molecular Weight Keratin, ERG, SPKINK1, Ki67 MIB1, Survivin and PTEN FISH and we have correlated staining results with clinical outcome. We also have made significant progress in testing TACOMA, an automated TMA scoring algorithm. We have completed staining of the TMAs for . Over the next year we will complete refinements of the infrastructure, complete pathologic review of the p27 and MUC1 biomarkers, and stain and evaluate several additional biomarkers which have received approval. We will complete statistical analysis for all of the completed biomarkers and others evaluated over the next year and plan to publish papers for each of the biomarkers over the next year. We wil also carry out outcome analysis for a panel of the biomarkers soon.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: